Explorez tous les épisodes du podcast Healthcare Unfiltered
| Titre | Date | Durée | |
|---|---|---|---|
| Episode 302: AI in Clinical Medicine With Anai Kothari | 27 oct. 2026 | 00:43:03 | |
How is artificial intelligence changing clinical medicine, and what will healthcare look like over the next five years? In this episode, Dr. Anai Kothari, a surgical oncologist and AI expert at the Medical College of Wisconsin, discusses the rapidly expanding role of AI in healthcare, from streamlining medical billing, coding, electronic medical records (EMRs), and physician documentation to improving radiology, pathology, predictive analytics, and clinical decision-making. Learn how AI is helping identify patients at risk for relapse, supporting personalized cancer treatment, assisting in the operating room, accelerating drug development, and transforming the future of patient care. | |||
| Episode 301: Wearables and the Heart With Greg Marcus | 20 oct. 2026 | 00:52:30 | |
On this episode of Healthcare Unfiltered, Gregory Marcus, MD, MAS, cardiologist and electrophysiologist at UCSF and a leading researcher in atrial fibrillation and digital health, joins the show to explore what wearables can—and cannot—tell us about cardiovascular health. | |||
| Episode 300 - Ghosts in the Blood: The Extraordinary History of CLL With Jeff Sharman | 13 oct. 2026 | 00:52:25 | |
In his first interview about Ghosts in the Blood, world-renowned hematologist/oncologist and CLL researcher Jeff Sharman, MD, takes us on a fascinating journey through the history of chronic lymphocytic leukemia—from its earliest recognition in the scientific literature in 1924 to the remarkable advances that have transformed CLL treatment. Along the way, Dr. Sharman brings the history to life with stories of the patients, physicians, scientists, rivalries, setbacks, and breakthroughs that shaped the field, revealing how discoveries in CLL helped drive the broader evolution of cancer medicine from chemotherapy to monoclonal antibodies, targeted therapies, and precision medicine. | |||
| Episode 299: AI and MRI Screening for Breast Cancer With Dan Bickford | 06 oct. 2026 | 00:31:21 | |
Chadi is joined by entrepreneur Dan Bickford, co-founder of Confirma and creator of the CADstream computer-aided detection software, to explore how artificial intelligence is transforming breast cancer screening with MRI. They discuss which women are most likely to benefit from breast MRI—particularly those with dense breast tissue—the evidence supporting AI-assisted interpretation as an FDA-cleared workflow tool, and how the technology complements radiologists to improve accuracy and efficiency. The conversation also examines why MRI screening is not recommended for all women with dense breasts, the practical barriers to broader adoption, and the potentially life-saving consequences of identifying the right patients for advanced imaging. | |||
| Episode two: Healthcare Unfiltered - Arabic Edition (رحله عبر المختبرات الطبيه مع اد نيڤين العبد و اد مي شريف) | 05 oct. 2026 | 00:55:12 | |
In this new episode of Healthcare Unfiltered - Arabic Edition, Nagla and Chadi host Drs. and Professors Nevine Elabd and Mai Sherif to discuss what happens inside the medical laboratories, and how new technological advances in the laboratory, including artificial intelligence, are aiding and helping patients and the doctors that care for them. Check it out, share, subscribe, and join the conversation. في حلقة جديدة من Healthcare Unfiltered – النسخة العربية، أستضيف أنا ونجلاء الدكتورتين والأستاذتين نيفين العبد ومي شريف في حوار شيّق نأخذكم فيه إلى داخل المختبرات الطبية لنتعرّف على ما يحدث خلف الكواليس، وكيف تُسهم أحدث التطورات التكنولوجية — وعلى رأسها الذكاء الاصطناعي — في تطوير عمل المختبرات، ودعم الأطباء، وتحسين رعاية المرضى. .شاهدوا الحلقة، شاركوها مع الآخرين، اشتركوا في البرنامج، وانضموا إلى الحوار | |||
| Episode 298 - The Caregiver's Burden: Lessons From an Oncologist Who Lost Her Mother to Cancer | 29 sept. 2026 | 00:31:14 | |
In this deeply personal episode, Allison A. Fitzgerald, MD, PhD, a pancreatic oncologist at Dana-Farber Cancer Institute, reflects on the experience of losing her mother to cancer and the story she courageously shared in ASCO Connection. She discusses what prompted her to publish such an intimate account, the unique perspective of serving as both an oncologist and a caregiver, the emotional support that sustained her, and how her family and others in her life responded to her essay. Dr. Fitzgerald also explores the often-overlooked burden placed on caregivers, why current support systems fall short, what changes are needed to better care for those caring for others, and how this life-changing experience reshaped her understanding of balance, grief, and compassion in medicine. | |||
| Episode 297: Keto Diet and Cancer With Thomas Seyfried | 22 sept. 2026 | 00:46:45 | |
In this thought-provoking episode, Chadi Nabhan sits down with Thomas Seyfried, PhD, professor of biology at Boston College, to explore his controversial and unconventional views on cancer metabolism, the ketogenic diet, and the role of sugar in cancer development. Dr. Seyfried explains the science behind metabolic therapy, the origins of the glucose ketone index (GKI), why ketogenic diets have long been used to treat epilepsy, and his belief that restricting glucose and glutamine can prevent cancer growth, challenging the widely accepted view that cancer is primarily a genetic disease. They also discuss whether healthy individuals should follow a ketogenic diet, how his research is being received by the oncology community, and the evidence behind these bold claims in a candid, spirited conversation that is sure to spark debate. | |||
| Episode 296: All Things Sarcoma With Neeta Somaiah | 15 sept. 2026 | 00:43:18 | |
Neeta Somaiah, MD, of The University of Texas MD Anderson Cancer Center, provides a comprehensive overview of bone and soft tissue sarcomas, exploring how molecular classification and histology guide treatment decisions, the major therapeutic breakthroughs and drug approvals that have reshaped the field over the past decade, and current approaches to curative-intent therapy, including surgery, radiation, and adjuvant treatment strategies. The conversation also examines the management of advanced sarcoma, highlighting recent advances, ongoing challenges, and where the field is headed for patients with these complex malignancies. | |||
| Episode 295: Integrative Approaches to Breast Cancer With Michael Karlfeldt | 08 sept. 2026 | 00:42:53 | |
Chadi speaks with Michael Karlfeldt, ND, PhD, a board-certified naturopathic doctor, integrative medicine expert, and author of Breast Cancer Breakthrough: Integrating Conventional & Natural Medicine for True Healing, about evidence-informed complementary approaches to breast cancer care. They discuss how nutritional strategies, stress management, sleep optimization, toxin reduction, and other supportive interventions can be safely integrated alongside conventional breast cancer treatments, the inspiration behind his book, and why his protocols are designed to complement—not replace—standard oncology care. The conversation also explores the challenges of limited clinical evidence for integrative medicine, how Dr. Karlfeldt evaluates available research, and what patients, caregivers, and oncology professionals should know about incorporating supportive therapies into comprehensive breast cancer treatment. | |||
| Episode 294 - How AI Helps Logistics in Oncology: The Story of ZoomLogi | 01 sept. 2026 | 00:34:29 | |
Chadi Nabhan sits down with Saad Shahzad, co-founder of ZoomLogi, to explore how AI is revolutionizing healthcare logistics by improving the delivery of high-value, time-sensitive therapies, including cell and gene therapies, specialty pharmaceuticals, and biologics. They discuss the costly challenges of shipment delays, chain-of-custody issues, and fragmented supply chain systems, and how ZoomLogi's AI-powered platform provides real-time visibility across carriers, predicts disruptions before they occur, and delivers precise shipment ETAs to help ensure life-saving treatments reach patients safely and on time. | |||
| Episode one: Healthcare Unfiltered - Arabic Edition (بين الفن والطب مع الفنان العالمي أحمد شاكر) | 28 août 2026 | 01:00:55 | |
On this inagural and special episode of Healthcare Unfiltered -Arabic Edition, Nagla and I host the world-renowned actor and artist, Mr. Ahmed Shaker, who candidly shares his career journey and how he almost went into medicine. Mr. Shaker who speaks 3-4 languages has risen to fame through many series that were watched by millions. He discusses with us how art can help patients and how artists can use their fame, reach, and people's trust to disseminate health information and to help people combat fake data that may be all over social media. Mr. Shaker also shares his journey as a caregiver of his wonderful mom who was affected by cancer and how he navigated the healthcare system. Mr. Shaker wants and is making a difference, and we are very grateful that he joined us on our show. Please share this show with your friends and colleagues, and don't forget to subscribe, review, and join the conversation نستضيف أنا ونجلاء الفنان والممثل العالمي الأستاذ أحمد شاكر، الذي يشاركنا بصراحة رحلته الفنية والمهنية، وكيف كاد أن يختار دراسة الطب بدلًا من الفن. يتحدث الأستاذ شاكر، الذي يجيد ثلاث إلى أربع لغات وحقق شهرة واسعة من خلال العديد من المسلسلات التي تابعها الملايين، عن الدور الذي يمكن أن يلعبه الفن في مساعدة المرضى، وكيف يستطيع الفنانون توظيف شهرتهم وتأثيرهم وثقة الجمهور بهم لنشر المعلومات الصحية الموثوقة والمساهمة في مواجهة المعلومات المضللة المنتشرة عبر وسائل التواصل الاجتماعي. كما يشاركنا تجربته الشخصية كمرافق ومساند لوالدته الرائعة خلال إصابتها بالسرطان، وما تعلمه من رحلته معها في التعامل مع منظومة الرعاية الصحية. الأستاذ أحمد شاكر حريص على إحداث فرق حقيقي، وهو بالفعل يفعل ذلك، ونحن ممتنون جدًا لانضمامه إلينا في هذه الحلقة المميزة. | |||
| Episode 293: Managing MPNs and the SENTRY Trial With Prithviraj Bose | 25 août 2026 | 00:26:03 | |
World-renowned MPN expert Dr. Prithviraj Bose of MD Anderson Cancer Center joins Chadi to explore the latest advances in myeloproliferative neoplasms (MPNs), including the molecular drivers of polycythemia vera, essential thrombocythemia, and myelofibrosis, and how these discoveries are reshaping patient care. The conversation then turns to the landmark phase 3 SENTRY trial, which evaluated frontline selinexor plus ruxolitinib versus ruxolitinib alone for patients with JAK inhibitor–naïve myelofibrosis—a rare blood cancer characterized by bone marrow scarring, splenomegaly, and debilitating symptoms. Dr. Bose discusses the trial's potentially practice-changing results, the benefits and limitations of the combination regimen, and what the data mean for the future standard of care in myelofibrosis. | |||
| Episode 292 - CELMoDs in Myeloma: A Report From EHA | 18 août 2026 | 00:27:31 | |
Chadi is joined by two of the world's leading multiple myeloma experts, Dr. Sagar Lonial of Emory University and Dr. Vincent Rajkumar of Mayo Clinic, for an in-depth discussion of the latest advances in multiple myeloma presented at the European Hematology Association (EHA) Congress in Stockholm. They explore the emerging class of cereblon E3 ligase modulators (CELMoDs), explaining how these next-generation therapies differ from existing immunomodulatory drugs, the science behind their mechanism of action, and why they are generating so much excitement in the field. The conversation also reviews the key clinical trial data unveiled at EHA, discusses where CELMoDs may fit into the evolving treatment landscape, and looks ahead to the breakthroughs that could shape multiple myeloma care in the years to come. | |||
| CÓMO TOMAMOS DECISIONES EN HEMATOLOGÍA? | 17 août 2026 | 00:46:22 | |
How is decision-making shaped in hematology? In a setting where evidence from randomized clinical trials, real-world data, and the uncertainties inherent in everyday clinical practice coexist, how do we analyze the available information to make the best treatment decisions for our patients? Cómo se construye la toma de decisiones en hematología? En un escenario donde conviven la evidencia de los estudios clínicos aleatorizados, los datos del mundo real y las incertidumbres inherentes a la práctica diaria, cómo analizamos la información disponible para tomar las mejores decisiones terapéuticas para nuestros pacientes? | |||
| Episode 291: APPs in Oncology With Corinne Shamehdi | 11 août 2026 | 00:42:06 | |
Advanced Practice Providers (APPs)—including physician assistants (PAs) and nurse practitioners (NPs)—are playing an increasingly vital role in meeting the growing demand for high-quality cancer care. Corinne Shamehdi, PA-C, a hematology/oncology physician assistant and educator with NCODA, sits down with Chadi and discusses why the APP workforce is expanding, how PAs and NPs are trained, the evolving relationship between APPs and physicians, and addresses common misconceptions surrounding their role in oncology practice. The conversation also explores licensure across state lines, career advancement opportunities, and how oncology APPs stay current with the rapid pace of new cancer therapies and clinical evidence, offering an inside look at one of the fastest-growing segments of the oncology workforce. NCODA is a non-profit organization that supports the full oncology care team through education, quality standards, and best practices. If you're an Oncology APP or a member of the oncology care team, you can learn more and join NCODA. Membership is complimentary. Join here: https://bit.ly/NCODAHealthcareUnfiltered Find out more about NCODA. | |||
| Episode 290: The ChemoCentryx Saga With Anish Koka | 04 août 2026 | 00:43:09 | |
Cardiologist and “The Doctor's Lounge” host Anish Koka, MD, joins the show to examine the extraordinary ChemoCentryx and Tavneos (avacopan) controversy, including the retraction of a New England Journal of Medicine clinical trial that played a key role in the drug's FDA approval for ANCA-associated vasculitis. Based on his Substack investigation, Dr. Koka breaks down the timeline of events, the concerns surrounding post hoc changes to trial endpoints, the FDA's response, and the far-reaching implications for clinical trial integrity, drug development, pharmaceutical regulation, and evidence-based medicine. Tune in for a thought-provoking discussion on scientific transparency, regulatory oversight, and what this high-profile case means for physicians, researchers, the pharmaceutical industry, and patients alike. | |||
| Episode 289 - Treating Leukemias: Past and Present With Hagop Kantarjian | 28 juil. 2026 | 00:44:20 | |
In this special episode, Chadi sits down with one of the most influential figures in modern leukemia research and care: Hagop M. Kantarjian, MD, Professor and Samsung Distinguished Leukemia Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. Dr. Kantarjian reflects on four decades of progress in leukemia treatment, discussing how the field has evolved from an era of limited therapeutic options to one transformed by groundbreaking scientific advances, while offering his perspective on risk stratification across favorable, less favorable, and high-risk leukemias. | |||
| Episode 288 - Leadership Lessons: From Bunker Hill to the Boardroom | 21 juil. 2026 | 00:53:22 | |
Chadi sits down with Andy Moye—author of From Bunker Hill to the Boardroom—to explore the battle-tested leadership principles that shaped his journey from military service to executive leadership in biotechnology, life sciences, molecular diagnostics, and artificial intelligence. Moye shares why empathy is the cornerstone of effective leadership, how leaders must develop “adaptive intelligence” by letting go of preconceived solutions and responding to evolving challenges, and the critical mistakes executives continue to make in healthcare today. | |||
| Episode 287 - RAS in Pancreatic Cancer: The RASolute 302 Study | 14 juil. 2026 | 00:38:58 | |
Chadi is joined by renowned gastrointestinal oncologists, Tanios S. Bekaii-Saab, MD, of Mayo Clinic, and Shubham Pant, MD, MBBS, of MD Anderson Cancer Center, to discuss the groundbreaking findings from the RASolute 302 trial, recently published in The New England Journal of Medicine and presented to a standing ovation during the plenary session at the 2026 ASCO Annual Meeting. Dr. Pant, a study author, provides an insider's perspective on how RAS inhibition is reshaping the treatment landscape for pancreatic cancer, including where these therapies may fit in the current treatment paradigm and how clinicians should manage their unique toxicity profiles. The conversation also looks ahead to the next generation of studies, including RASolute 303 and RASolute 304, and what these trials could mean for the future of precision medicine in pancreatic cancer. | |||
| Episode 286: The Status of NGS in Cancer With Ezra Cohen | 07 juil. 2026 | 00:41:24 | |
Chadi sits down with Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus AI, for an in-depth discussion on the evolving role of next-generation sequencing (NGS) across the cancer continuum. Together, they explore how tissue-based testing, liquid biopsy, and measurable residual disease (MRD) assessments are reshaping precision oncology, why NGS remains underutilized in many patients, and the educational efforts needed to ensure genomic testing is ordered and applied appropriately to improve outcomes. Dr. Cohen also examines the growing role of artificial intelligence in interpreting and integrating genomic data, including Tempus' embedded AI tools designed to support both clinicians and patients. | |||
| LOS DIFERENTES SIGNIFICADOS DE LA PALABRA CÁNCER EN HEMATOLOGÍA | 01 juil. 2026 | 00:43:52 | |
Healthcare Unfiltered Podcast and FASE 3 Podcast are collaborating on a new venture called "Hematology Sin Filtros" - a new podcast in Spanish that will be broadcasted once a month discussing various topics in hematology and cancer. Please share with your friends, colleagues and subscribe and join the conversation. | |||
| Episode 285 - Gabby’s Journey: Cancer, Hope, and Resilience | 30 juin 2026 | 00:47:01 | |
In this deeply personal episode, Gabby shares her extraordinary journey of being diagnosed with stage IV metastatic colorectal cancer with liver involvement during the final stages of her pregnancy. She discusses the emotions and decisions surrounding her diagnosis, what she looked for when choosing her oncology team, how openly she communicated with her husband and young children, and the realities of navigating cancer treatment while welcoming a new baby. Gabby also reflects on documenting her experience in real time on social media, exploring both the support and challenges that come with sharing such an intimate journey publicly, while offering insight into the many clinical and personal decisions she has faced along the way. | |||
| Episode 284: The Evolution of Liver Transplant for Cancer With Maen Abdelrahim | 23 juin 2026 | 00:39:06 | |
Maen Abdelrahim, MD, PhD, Section Chief of Gastrointestinal Medical Oncology at Houston Methodist Neal Cancer Center—home to the nation’s highest-volume liver transplant program—joins the show to discuss the expanding field of transplant oncology, including which patients with hepatocellular carcinoma, colorectal cancer metastatic to the liver, biliary cancers, and intrahepatic cholangiocarcinoma may benefit from liver transplantation. He explores the history of liver transplantation and the development of the Milan criteria, how those advances paved the way for transplant oncology as a multidisciplinary specialty, and the ongoing educational gaps surrounding transplant eligibility and referral. Dr. Abdelrahim also shares insights from his book, “Transplant Oncology: A Frontier in Multidisciplinary Cancer Care,” while discussing the evolving role and safety of immunotherapy and ctDNA in the peri-transplant setting and the future of cancer care for patients once considered untreatable. | |||
| Episode 283 - MAID in America: Navigating Choice, Compassion, and Controversy | 16 juin 2026 | 00:50:42 | |
Chadi hosts Dr. Chandana Banerjee of City of Hope and Kevin Diaz, CEO and President of Compassion & Choices, for a thoughtful conversation about Medical Aid in Dying (MAID) – what it is, who qualifies, how the process works, and why it remains one of the most debated issues in modern healthcare. Together, they explore the legal, ethical, and cultural complexities surrounding MAID, including the differences between MAID, assisted suicide, and euthanasia, the role of physicians and hospice care, the history and legal challenges of MAID legislation in the US, and the deeply personal realities patients and families face when navigating terminal illness, especially when loved ones disagree about care goals or when palliative and hospice care are no longer enough. | |||
| Episode 282: TIL Therapy and Melanoma With Dan Olson | 09 juin 2026 | 00:35:44 | |
Chadi sits down with Dr. Daniel Olson to discuss the growing excitement surrounding tumor-infiltrating lymphocyte (TIL) therapy in melanoma, including how these personalized cellular therapies are created (and sometimes engineered in the lab), the logistical challenges of collection and reinfusion, and the clinical data that led to FDA approval based on a single-arm study. Dr. Olson also explores treatment sequencing with immunotherapy and targeted therapy, the severity and duration of associated toxicities, response rates seen in practice, and the expanding potential for TIL therapy in other malignancies such as lung and cervical cancers, offering a practical and forward-looking look at one of the most promising advances in solid tumor oncology. | |||
| Episode 281: Precision Oncology in India With Sewanti Limaye | 26 mai 2026 | 00:43:33 | |
Chadi is joined by Dr. Sewanti Limaye to discuss what precision oncology looks like in India, exploring the realities of access, affordability, infrastructure, and innovation in cancer care. Drawing on her experience training and practicing in the United States before returning to Mumbai to lead oncology and translational research programs, Dr. Limaye explains which genomic tests, liquid biopsies, and targeted therapies are currently available in India, the challenges surrounding out-of-pocket costs and insurance coverage, and why helping even a small percentage of patients access precision medicine can have a major impact. The conversation also covers clinical trial capabilities, lab turnaround times, international players in the liquid biopsy space, and the complexities of FDA-approved drugs that remain unavailable for prescription in India. | |||
| Episode 280 - Cooperative Group Trials: Now and Tomorrow With Sue Yom | 19 mai 2026 | 00:49:32 | |
Chadi sits down with sit down with Sue S. Yom, MD, PhD, FASTRO—radiation oncologist at UCSF, Editor-in-Chief of the International Journal of Radiation Oncology Biology Physics, and leader within NRG Oncology—to explore the critical role of cooperative groups in advancing cancer research. She unpacks their history, the benefits and challenges of large-scale collaboration, and how federal funding and partnerships with industry shape the design and execution of clinical trials. Dr. Yom also shares insights from her editorial perspective and highlights what’s ahead in radiation oncology, including the growing role of biomarkers, personalized treatment strategies, and smarter sequencing of therapies. | |||
| Episode 279 - CGT in the Community: Challenges and Solutions | 12 mai 2026 | 00:40:02 | |
Gary L. Simmons, DO, MSHA—physician and entrepreneur in a Virginia community practice—dives into the rapidly evolving world of cell and gene therapy (CGT), including bone marrow transplant, CAR-T, and TILs, and what it takes to bring these cutting-edge treatments safely into the community setting. He unpacks the operational, financial, and workforce challenges of building and scaling a CGT program outside of academia, from payer hesitancy and 340B pressures to the infrastructure and staffing required for success. The conversation also explores the future of CGT, how innovation may reshape access, and why community practices could play a critical role as demand outpaces traditional academic centers. | |||
| Episode 278: What’s New in Multicancer Early Detection With Tom Beer | 05 mai 2026 | 00:32:18 | |
Returning guest Dr. Tom Beer, Chief Medical Officer for Multicancer Early Detection (MCED) at Exact Sciences, joins the show to break down the promise and complexity of MCED testing—what it is, the clinical gap it aims to fill, and how it could reshape cancer diagnostics. He explores which patient populations may benefit most, the current limitations across different cancer types, and whether MCED tests are poised to complement or replace traditional single-cancer screening approaches. The conversation also tackles key nuances like balancing sensitivity and specificity, interpreting negative results, and how clinicians and patients should think about repeat testing in an evolving screening landscape. | |||
| Episode 277 - When “Yes” Becomes Too Much: Confronting Physician Burnout | 28 avr. 2026 | 00:50:07 | |
Chadi sits down with Dan Golden, MD, MHPE, Associate Professor of Radiation Oncology at Rush University, to discuss his deeply personal and recently published account of physician burnout. He shares the mental and physical toll of burnout, clarifies how it differs from depression and anxiety, and reflects on the pressures of academic medicine’s “say yes to everything” culture that leaves little room for setting boundaries. From masking symptoms and navigating a job change that added stress, to ultimately taking leaves of absence and undergoing intensive therapy, Dr. Golden offers an unfiltered look at how dire things became—and why speaking out may help others facing the same struggle. | |||
| Episode 276: Radiation Therapy for GI Cancer With Nina Sanford | 21 avr. 2026 | 00:36:09 | |
Chadi sits down with Nina Sanford, MD, Chief of Gastrointestinal Radiation Oncology Service at UT Southwestern, to explore the evolving landscape of radiation therapy in upper and lower GI malignancies. They discuss how advances in systemic treatments are reshaping radiation strategies, current standards of care in colorectal, gastroesophageal, pancreatic cancers, and liver cancers, and the growing role of organ preservation and adaptive radiation in improving patient outcomes. Dr. Sanford also shares insights into emerging clinical trials, personalized treatment approaches, and what she is most excited about in the future of GI radiation oncology. | |||
| Episode 275: PAVING the Path After Breast Cancer With Amy Comander | 14 avr. 2026 | 00:44:05 | |
Chadi sits down with Amy Comander, MD, a breast cancer medical oncologist at Mass General Brigham Cancer Institute and author of “Paving Your Path Through Breast Cancer and Beyond,” to discuss how patients can take control of their health and quality of life after a breast cancer diagnosis. She shares the inspiration behind her book and offers a practical, lifestyle medicine–focused roadmap—covering nutrition, physical activity, sleep, stress management, and social connection—along with her “PAVING” framework for sustainable change. The conversation also explores her perspectives on popular diets, the psychological aspects of survivorship, and the key takeaways she hopes patients and caregivers carry with them beyond treatment. | |||
| Episode 274 - Food and Cancer: The Truth | 07 avr. 2026 | 00:41:40 | |
Chadi sits down again with Dr. Urvi Shah for an in-depth, evidence-driven exploration of the often confusing relationship between food and cancer. They dive into how nutritional research is actually conducted—and why it’s so challenging—while separating widely regarded myths from what high-quality data truly support, including nuanced discussions on processed foods, red meat, plant-based diets, ketogenic diets, intermittent fasting, and alcohol use. Dr. Shah also offers practical, science-backed recommendations for cancer prevention in the general population, as well as thoughtful guidance on how patients might approach diet and lifestyle changes after a cancer diagnosis. | |||
| Episode 273 - Radiation Oncology: Past and Future | 31 mars 2026 | 00:45:57 | |
Chadi sits down with Dr. William “Bill” Small, Jr., a nationally recognized radiation oncologist and cancer center director at Loyola University Chicago, to explore the evolution of radiation oncology from its historical foundations to its rapidly advancing future. They discuss cutting-edge developments including proton therapy, radiopharmaceuticals, and the growing integration of molecular tumor profiling with precision radiation techniques, as well as the field’s increasing collaboration with medical oncology. Dr. Small also shares insights on mentoring the next generation of researchers, expanding clinical trials in radiation oncology, and addressing critical challenges such as overtreatment while shaping the future of the discipline. | |||
| Episode 272: Genomics for Rare Diseases With Katherine Stueland | 24 mars 2026 | 00:38:10 | |
Chadi sits down with Katherine Stueland, President and CEO of GeneDx, to explore how genomic sequencing is transforming the diagnosis of rare diseases—especially for pediatric patients who often endure years searching for answers. She discusses the company’s work analyzing the full genome to uncover gene–disease correlations, its efforts to bring advanced genetic testing directly into pediatricians’ offices through education and access initiatives, and how its massive rare-disease dataset is helping clinicians deliver faster, more precise diagnoses. The conversation also looks ahead to the expanding role of genomics in adult conditions such as neurodegenerative diseases, the potential of partnerships with biopharma, and how AI-driven analysis of large genomic datasets is accelerating discovery and precision medicine. | |||
| Episode 271: Behind the Scenes of “The Pitt” With Sylvia Owusu-Ansah | 17 mars 2026 | 00:47:09 | |
Chadi sits down with Dr. Sylvia Owusu-Ansah, a pediatric emergency physician at UPMC, to discuss her role as a medical advisor for the HBO Max series “The Pitt” and how she helped bring real-world authenticity to the show. She explains how the writers first approached her and asked a key question—what stories have not yet been told on medical dramas—which led her to highlight issues such as the challenges of sickle-cell pain management and share the powerful real-life story of a 17-year-old patient that ultimately inspired a storyline in the series. Dr. Owusu-Ansah also reflects on how her own experiences, including those as a Black physician in emergency medicine, informed the perspectives she brought to the writers’ room, and she discusses what “The Pitt” portrays most accurately about life in the ER and how the show differs from traditional medical dramas in its approach to realism. | |||
| Episode 270: Translational Research Questions in Small Cell Lung Cancer | 10 mars 2026 | 00:40:09 | |
Chadi sits down with Misty Shields, MD, PhD, Assistant Professor of Clinical Medicine in the Division of Hematology/Oncology at Indiana University School of Medicine, to explore the evolving translational research landscape in small cell lung cancer. Together, they discuss the pivotal shift in how small cell lung cancer is biologically classified, the modern roles of prophylactic cranial irradiation and immunotherapy, and how these approaches are being refined through ongoing research. Dr. Shields also highlights the importance of next-generation sequencing, biomarker development, and the exciting compound combinations under investigation—offering a compelling look at how today’s lab discoveries are shaping tomorrow’s clinical breakthroughs. | |||
| Episode 269: The Pain Brokers and Tort Law With Beth Burch | 03 mars 2026 | 00:48:00 | |
Chadi sits down with award-winning legal scholar Elizabeth (Beth) Chamblee Burch to explore “The Pain Brokers: How Con Men, Call Centers, and Rogue Doctors Fuel America’s Lawsuit Factory,” her deeply reported investigation into a multilevel scam involving a pelvic mesh product that preyed on vulnerable patients and exploited mass tort litigation. Together, they discuss how she uncovered her sources and evidence, the harrowing stories of the women caught up in this web of telemarketing, shady medical referrals, and legal profiteering, and what the fallout reveals about the broader tort law system. | |||
| Episode 268: Everything ADCs in Cancer With Paolo Tarantino | 24 févr. 2026 | 00:35:30 | |
Paolo Tarantino, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, joins Chadi for a deep dive into the rapidly evolving world of antibody-drug conjugates (ADCs)—sometimes dubbed “super-chemotherapies.” He traces the fascinating origins of the ADC concept, including a centuries-old scientific insight that foreshadowed their development, and explains the biology behind how these targeted therapies deliver potent cytotoxics directly to cancer cells across tumor types. Dr. Tarantino also reflects on launching his career alongside the infancy of modern ADCs, explores innovations like multi-payload constructs, and weighs in on whether ADCs could ultimately replace conventional chemotherapy as research continues to push the field forward. | |||
| Episode 267: State of Peer Review and Medical Publishing With Nora Disis | 17 févr. 2026 | 00:58:02 | |
Chadi sits down with Nora Disis, MD—Editor in Chief of JAMA Oncology and professor at Fred Hutchinson Cancer Center—for a candid, wide-ranging discussion on the modern state of peer review and medical publishing. Dr. Disis reflects on the founding of JAMA Oncology and her role as its inaugural Editor in Chief, then pulls back the curtain on what actually happens when a manuscript is submitted (yes, she reads every one), how impact factors shape—and sometimes distort—the field, and what truly defines a high-quality peer reviewer. From the promises and pitfalls of AI to the pressures facing academic publishing today, this is a raw, thoughtful, and at times critical look at how medical evidence gets vetted and shared with the world. | |||
| Episode 266 - History of Viruses: Kill Switch | 10 févr. 2026 | 01:08:42 | |
Award-winning stem cell transplant pioneer, Dr. Richard Burt, discusses his book “Kill Switch: The History of How Viruses Shaped Humanity and Led to COVID-19,” guiding listeners through the deep, often surprising role viruses like smallpox, polio, HIV, and COVID-19 have played in shaping human civilization and global health responses. With factual clarity and a historian’s eye, Dr. Burt explains the development of scientific understanding and vaccines without political agenda, offering historical perspective that sheds light on the ups and downs of vaccine innovation and what we can learn from the COVID-19 era. | |||
| Episode 265: ASCO GI Updates: Special Episode | 05 févr. 2026 | 00:58:07 | |
Drs. Shaalan Beg, Shruti Patel, and Emil Lou—the “Only Oncologists in the Building”—offer an in-depth, clinically focused review of the most important research presented at the ASCO GI Annual Meeting. The conversation spans the rising incidence and outcomes of early-onset colorectal cancer, survivorship considerations, and a nuanced discussion of ctDNA in the adjuvant setting for high-risk stage II disease, including whether its role has evolved from purely prognostic to truly predictive. They also critically analyze practice-defining trials such as BREAKWATER in BRAF V600E–mutated metastatic colorectal cancer, COMMIT in dMMR/MSI-H disease, upper GI studies including HORIZON-GEA-01, MATTERHORN, and ILUSTRO, along with meaningful updates in pancreatic and hepatobiliary cancers—ultimately weighing which data should influence clinical practice today versus what remains on the horizon. | |||
| Episode 264: Oncology Career Paths With the Two Onc Docs | 03 févr. 2026 | 00:55:01 | |
In this cross-collaboration episode, Drs. Sam Armstrong and Karine Tawagi—hosts of the “Two Onc Docs” podcast—join the show to share their personal journeys into oncology and the inspiration behind launching a podcast for the oncology community. The conversation then expands into a candid, practical discussion of oncology career paths, offering fellows and early-career physicians real-world guidance on choosing a first job, negotiating contracts and compensation, evaluating mentorship, and balancing professional goals with life outside of medicine. From academic practice to alternative stakeholder roles, this honest dialogue unpacks the many decisions that shape a sustainable and fulfilling career in medicine. | |||
| Episode 263: ADCs in Breast Cancer: What to Know With VK Gadi | 27 janv. 2026 | 00:36:27 | |
VK Gadi, MD, PhD, of the University of Illinois Cancer Center, joins the show for a deep dive into antibody-drug conjugates (ADCs) in breast cancer, tracing the history and basic science that fueled their development and early interest in the field. Dr. Gadi breaks down where ADCs currently fit in breast cancer care, including key toxicities, evolving data presented at ESMO, and findings that may support FDA approval in early-stage and neoadjuvant HER2-positive disease. The conversation also explores advances in TROP-2–expressing and HER2-low disease, along with practical insights on incorporating and sequencing these agents in earlier lines of therapy. | |||
| Episode 262: MRD and ctDNA in Lymphoma With Megan Melody | 20 janv. 2026 | 00:48:06 | |
Returning guest Megan Melody, MD—lymphoma and CAR-T hematologist at Tampa General Hospital and the University of South Florida—joins the show for a practical, data-driven discussion on the evolving role of measurable residual disease (MRD) and circulating tumor DNA (ctDNA) in lymphoma. The conversation explores which lymphoma subtypes benefit most from MRD assessment, the available commercial assays and their sensitivity and specificity, how MRD and PET imaging should be used together (or not), and how to manage real-world scenarios such as PET-positive/ctDNA-negative patients at the end of therapy. Dr. Melody also reviews NCCN guidance, emerging frontline data in large B-cell lymphoma, and how both academic and community clinicians can translate these tools into everyday treatment decisions. | |||
| Episode 261: Rebooting Cancer Care With Doug Flora | 13 janv. 2026 | 00:40:59 | |
Returning guest Doug Flora, MD, LSSBB, practicing oncologist and healthcare innovator, joins the show to discuss his new book Rebooting Cancer Care and his pragmatic vision for how artificial intelligence is reshaping oncology today. Dr. Flora explores how AI is already being leveraged to accelerate drug discovery and development, redesign smarter clinical trials, and support more informed, efficient decision-making—while emphasizing that these tools are meant to augment and “save” the oncologist, not replace them. Written for clinicians, industry leaders, patients, and caregivers alike, his book breaks down complex technology into accessible insights, highlighting how AI can reduce burnout, restore human connection in care, and help build a more sustainable, patient-centered cancer ecosystem. | |||
| Episode 260: TNBC Now and the Future With Greg Vidal | 06 janv. 2026 | 00:34:41 | |
Chadi sits down with Gregory Vidal, MD, PhD, medical oncologist at the West Cancer Center, for a comprehensive, state-of-the-field discussion on triple-negative breast cancer (TNBC). Dr. Vidal walks listeners through how TNBC emerged as a diagnosis of exclusion, who is most commonly affected, current treatment paradigms and sequencing in early-stage and metastatic disease, and key considerations around surgery, recurrence risk, and unresolved questions. The conversation also explores modern decision-making in metastatic TNBC, including PD-L1 testing, first- and second-line strategies, antibody–drug conjugates versus chemotherapy, PARP inhibitors for BRCA-mutated disease, and the critical role of clinical trials in shaping the future of care. | |||
| Episode 259: AI Enhancing Cancer Diagnosis With Jonathan Chen | 30 déc. 2025 | 00:36:18 | |
Jonathan Chen, MD, PhD—Assistant Professor of Medicine and Biomedical Informatics at Stanford University—joins the show and offers a pragmatic look at how data science and AI can be meaningfully integrated into everyday medical practice. He breaks down how complex clinical data can be translated into intuitive, real-world use cases, from algorithm-driven decision support in cancer diagnosis to recommendations that fit seamlessly into day-to-day clinician workflows. The conversation also explores whether these approaches can scale across specialties and procedures, while thoughtfully addressing the ethical considerations that come with deploying AI in clinical care. | |||
| Episode 258: AI Now and Later With Sanjay Juneja | 23 déc. 2025 | 00:53:53 | |
Chadi sits down with Sanjay Juneja, MD—board-certified hematologist/oncologist, healthcare futurist, and physician executive—to demystify artificial intelligence and explain what it truly means for patient care today and in the years ahead. Dr. Juneja breaks down how AI is already influencing healthcare broadly and oncology specifically, from generative AI applications to emerging tools that can analyze voice patterns to estimate physiologic markers like glucose levels. They also explore where AI is headed over the next 5–10 years, the risks and potential for misuse outside of medicine, strategies to minimize AI error, and whether human experts will continue to play a critical role between AI and patients. | |||
| Episode 257: Reflections of an ASCO President With Robin Zon | 16 déc. 2025 | 00:49:47 | |
In this reflective and wide-ranging conversation, ASCO President Robin Zon, MD, FACP, FASCO, looks back on the formative moments that led her to oncology and the grit required to build a thriving community-based research program while balancing the demands of leadership, motherhood, and clinical practice. She shares the path that took her from ASCO member and fellow in 1997 to the presidency, unpacking the three-pillar theme she crafted for her term and the accomplishments she’s most proud of, especially those rooted in her identity as a community oncologist connecting with colleagues nationwide. Dr. Zon also weighs in on emerging innovations like AI, the evolving realities of community practice, and the broader challenges she believes oncology and the healthcare system must confront in the years ahead. | |||